Heat Shock Protein 70 Inhibits the Activity of Influenza A Virus Ribonucleoprotein and Blocks the Replication of Virus In Vitro and In Vivo

Gang Li1,3, Junjie Zhang1,3, Xiaomei Tong1, Wenjun Liu2, Xin Ye1*

1 Center for Molecular Immunology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, P. R. China, 2 Center for Molecular Virology, CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, P. R. China, 3 Graduate University of Chinese Academy of Sciences, Beijing, P. R. China

Abstract

Background: Heat shock protein 70 (Hsp70) was identified as a cellular interaction partner of the influenza virus ribonucleoprotein (RNP) complex. The biological significance of the interaction between Hsp70 and RNP has not been fully investigated.

Principal Findings: Here we demonstrated that Hsp70 was involved in the regulation of influenza A viral transcription and replication. It was found that Hsp70 was associated with viral RNP by directly interacting with the PB1 and PB2 subunits, and the ATPase domain of Hsp70 was required for the association. Immunofluorescence analysis showed that Hsp70 was translocated from the cytoplasm into the nucleus in infected cells. Then we found that Hsp70 negatively regulated the expression of viral proteins in infected cells. Real-time PCR analysis revealed that the transcription and replication of all eight viral segments were significantly reduced in Hsp70 overexpressed cells and greatly increased as Hsp70 was knocked down by RNA interference. Luciferase assay showed that overexpression of Hsp70 could inhibit the viral RNP activity on both vRNA and cRNA promoters. Biochemical analysis demonstrated that Hsp70 interfered with the integrity of RNP. Furthermore, delivered Hsp70 could inhibit the replication of influenza A virus in mice.

Significance: Our study indicated that Hsp70 interacted with PB1 and PB2 of RNP and could interfere with the integrity of RNP and block the virus replication in vitro and in vivo possibly through disrupting the binding of viral polymerase with viral RNA.

Introduction

Influenza A virus is a single-stranded, negative-sense RNA virus with eight genomes, belonging to the family Orthomyxoviridae. In the nucleus, eight genomes are capsidated by multiple copies of nucleoproteins and viral heterotrimeric polymerase complex, including PA, PB1, and PB2. The complex, namely viral RNP, is required for viral transcription and replication. The transcription of vRNA is initiated by use of short capped RNA oligonucleotides as primers which are snatched from host cellular mRNA by viral polymerase. Such primers contain the cap structure at the 5' ends followed by 9–15 nucleotides [1]. The transcription terminates at a sequence of five to seven uridines located 15 to 17 nucleotides from the 5' end of vRNA templates, where viral polymerase complex stutters by the addition of poly(A) tail. In contrast, the replication includes the intermediate complementary RNA synthesis which is positive-sense RNA and serves as the template for synthesis of progeny vRNA. The replication does not need primer and guarantees the fidelity.

Though the transcription and replication are fulfilled by viral polymerase complex, the three subunits of RNP have different functions. PB1 subunit is the core of the complex and has the polymerase activity [2,3], and vRNA and cRNA promoter binding activities [4,5], while PB2 is responsible for cap recognition [6,7]. PA has multiple functions such as protease activity causing the degradation of its associated partner and itself [8], endonuclease activity [9,10], promoter binding activity [11,12], virus assembly [13], and N-terminal of PA is involved in cap binding [14].

Some host factors are involved in replication and transcription of the influenza virus genome [15]. RanBP5 was found to interact with either PB1 or PA-PB1 heterodimer and help PA-PB1 dimer to enter the nucleus to form PA-PB1-PB2 complex [16]. Ebp1 was identified to interact with PB1 subunit and interfered with viral RNA synthesis in vitro, indicating that it was an inhibitor of influenza virus polymerase [17]. In addition, Hsp90 was identified...
Hsp70 interacted with PB1 and PB2 subunits of RNP

Results

Hsp70 interacted with PB1 and PB2 subunits of RNP

It was known that Hsp70 was associated with RNP complex [39,40]. To understand the significance of the association, we examined which subunit(s) of RNP that Hsp70 interacts with. 293T cells were co-transfected by Myc-Hsp70 with FLAG-NP, FLAG-PA, PB1cFLAG, or FLAG-PB2 plasmid, respectively. The total cell extracts were prepared and immunoprecipitated with anti-FLAG antibody followed by immunoblotting with anti-Myc antibody. The result showed that Hsp70 interacted with PA, PB1, and PB2 but not NP (Fig. 1A). We also examined whether endogenous Hsp70 could interact with PA, PB1, and PB2 in infected cells. 293T and MDCK cells were infected, and then the total cell extracts were prepared and subjected to immunoprecipitation with anti-Hsp70 antibody and immunoblotting with anti-PA, anti-PB1 or anti-PB2 antibody. The results showed that both PB1 and PB2 (Fig. 1B, C) interacted with endogenous Hsp70 in both cell lines. There was no detectable interaction between PA and endogenous Hsp70 (data not shown).

GST pull-down assays were carried out to confirm the direct interaction of Hsp70 with PB1 and PB2. As shown in Fig. 2A, B Hsp70 interacted with PB1 (aa79-659) which included cRNA promoter binding domain, part of cRNA promoter binding domain, and RNA polimerization motif [5,42]. The data in Fig. 2C, D illustrated that Hsp70 interacted with N-terminal domain (aa1-521) of PB2 which included the NP binding domain [43].

Hsp70 could be divided into two functional domains, the N-terminal ATPase domain and the C-terminal protein binding domain (PBD) in which there was EEDV motif. To examine which domain of Hsp70 was required for its interaction with PB1 and PB2, full length and truncated forms of Hsp70 were generated for GST pull-down assay. As shown in Fig. 2E, the ATPase domain was required for its direct interaction with PB1 (aa79-659) and PB2 (aa1-521).

Hsp70 was translocated into nucleus post-infection

Hsc70 interacted with M1 and the interaction was required for their own replication [32,33,34,35,36]. Hsp70 was found to inhibit virus infection [29,30,31]. Nevertheless, some viruses could utilize Hsp70 to help their own replication [32,33,34,35,36,37]. For influenza virus Hsp70 was identified to be involved in regulation of viral life cycle. Hsc70 interacted with M1 and the interaction was required for viral production [38]. Hsp70 was found to bind to ribonucleoprotein complex, which prevented M1 from binding to vRNP so that the nuclear export of vRNP was inhibited [39]. Proteomic data confirmed that Hsp70 was the interaction partner of influenza virus ribonucleoprotein complex [40]. It was reported that a higher level of Hsp70 was associated with vRNPs of influenza A/Ann Arbor/6/60 virus which was defective in replication compared with those of rWT virus [41]. However, it is not clear whether the interaction between Hsp70 and RNP has any effect on the polymerase activity.

In this study, we demonstrated that Hsp70 negatively regulated influenza virus RNP activity. It interacted with PB1 and PB2 subunits of RNP and was translocated from the cytoplasm to the nucleus in infected cells. Furthermore, Hsp70 interfered with the integrity of RNP, and then negatively regulated the viral transcription and replication.

Induction of Hsp70 with PGA1 inhibited the transcription and replication of influenza A virus genomes

In order to understand the biological function of Hsp70 on influenza virus replication, cells were infected, treated with PGA1, which was known to induce the overexpression of Hsp70 as reported [44]. The supernatants were harvested to examine the viral titers by plaque assay at different time points post-infection. The data showed that the viral titers in the supernatants from PGA1-treated A549 cells were reduced at 6 h and 12 h post-infection in comparison with the control (Fig. 4A), which was consistent with the result of others [39]. The reduced M1 protein level from the virion of the supernatants confirmed that the PGA1-treatment caused the decrease of released virion (Fig. 4B, C).

We wondered if the effect of Hsp70 on the viral titers was due to the decreased level of viral proteins. The total cell extracts were prepared at indicated time points for immunoblotting with anti-Hsp70, anti-M1, anti-NP, and anti-beta-actin antibodies. The protein level of Hsp70 increased as expected while both M1 and NP protein levels were reduced in PGA1-treated A549 (Fig. 4D, E) and MDCK (Fig. 4F, G) cells in comparison with those in untreated cells.

To determine whether the inhibitory effect of PGA1 on viral proteins level was due to the inhibition of the transcription and replication of viral genomes, the amounts of mRNA, vRNA and cRNA of eight genomes were measured. A549 cells were infected and then treated with PGA1. The total RNAs were prepared at 0 h post-infection and the amounts of mRNA, vRNA, and cRNA were quantified by real-time RT-PCR. The data showed that mRNA, vRNA, and cRNA levels of all eight genomes were greatly reduced in PGA1-treated cells (Fig. 5A, B, C). These results indicated that PGA1 treatment inhibited viral transcription and replication so as to reduce viral proteins level and viral titer.

The transcription and replication of influenza A virus genomes were up-regulated in Hsp70 depleted cells

To confirm that the inhibitory effect of PGA1 on the viral transcription and replication is indeed due to the induction of Hsp70, we took the approach of RNA interference to knock down...
the endogenous Hsp70 and analyze the viral transcription and replication. HeLa cells were used in this experiment because the siRNA can efficiently knock down the expression of Hsp70 in this cell line. HeLa cells were transfected with Hsp70 siRNA or control siRNA, and then infected with influenza A virus for 7 h. Total RNAs were isolated and subjected to real-time RT-PCR for mRNA, vRNA and cRNA. The results showed that the mRNA, vRNA, and cRNA levels of all eight genomes increased in Hsp70
Figure 2. Hsp70 interacts with PB1 and PB2 directly. The GST-fused PB1 mutants (A, B) or GST-fused PB2 (C, D) mutants were generated. The interaction between GST-PB1 mutants (B) or GST-PB2 mutants (D) and His-Hsp70 was analysed by GST pull-down assay and Western blot (upper panel), the CBB staining of purified proteins were shown in lower panel. (A, C) Binding activity is indicated as ‘+’, no significant binding activity as ‘−’. (E) The schematic map of Hsp70 and its mutants. (F) His-Hsp70, His-Hsp70ΔEED, His-Hsp70 ATPase domain and His-Hsp70 PBD were prepared and subjected to GST pull-down assays with GST-PB1(79–659) (upper left panel), GST-PB2(1–521) (upper right panel) and GST as negative control, and the purified His-Hsp70 and its mutants were subjected to CBB staining (lower panel). Arrows indicated purified proteins of CBB staining. These experiments were repeated twice with identical results.

doi:10.1371/journal.pone.0016546.g002
depleted cells compared with those in control cells (Fig. 5D, E, F). Consistently the protein levels of M1 and NP also increased in Hsp70-depleted cells (Fig. 6A, B). These results suggested that knockdown of Hsp70 favored viral transcription and replication.

Hsp70 inhibited both transcription and replication of RNP

The primary transcription of input vRNP initiates when host cell is infected with influenza virus, followed by the replication producing progeny vRNP which is used to carry on subsequent secondary transcription. Since mRNA, vRNA, and cRNA levels increased in Hsp70-depleted HeLa cells, we wondered whether the increased mRNA level was caused by increased progeny vRNA or the direct effect of Hsp70 on primary transcription of input vRNP. It has been reported that cycloheximide (CHX), an inhibitor of protein synthesis, inhibited the transition from primary transcription to replication [45], therefore we could examine whether Hsp70 affect the primary transcription by using CHX to block the synthesis of progeny vRNP. CHX treatment did not affect the knockdown of endogenous Hsp70 in HeLa cells (Fig. 7A), then real-time RT-PCR results showed that the amounts of mRNA of NP and NS segments increased 2-3 fold in the presence of CHX and 4-5 fold in the absence of CHX in Hsp70 depleted HeLa cells (Fig. 7B). These data indicated that removing Hsp70 in the absence of replication caused the increase of mRNA level, but the increase was higher if both transcription and replication occurred, suggesting that Hsp70 negatively regulated both transcription and replication.

Hsp70 inhibited the activity of the influenza virus polymerase in a dose-dependent manner

To examine whether Hsp70 could regulate the activity of influenza virus polymerase, we took the approach of luciferase assay with vRNA and cRNA promoters. 293T cells were co-transfected with multiple plasmids as followed (i) the expression vectors encoding influenza virus polymerase subunits and NP; (ii) pH21-vNS-Luc or pH21-cNS-Luc reporter plasmid; and (iii) pCMV-Myc-Hsp70 in different doses or pcDNA3.1 as negative control. The cell lysates were subjected to luciferase assay and Western blot. The data of luciferase assay showed that relative luciferase activities under both vRNA and cRNA promoters in Hsp70 overexpressed cells were much lower than those in control cells in a dose-dependent manner (Fig. 8A), which indicated that Hsp70 inhibited the activity of viral polymerase complex on both vRNA and cRNA promoters. The immunoblotting results showed that the levels of RNP proteins were similar in the cells transfected with or without Myc-Hsp70 (Fig. 8B).

To examine which domain of Hsp70 was required for the inhibitory effect, we generated the truncated forms of Hsp70 and performed luciferase assay. The data showed that ATPase domain...
had similar inhibitory activity as full length, PBD partially inhibited the activity of viral polymerase but EEVD motif was not required (Fig. 8C). The immunoblotting data showed that the expression of RNP subunits and truncated forms of Hsp70 in transfected cells were similar except that the expressions of PA and PB2 were higher in Myc-Hsp70 ATPase-transfected cells (Fig. 8D).

**Hsp70 interfered with the integrity of RNP**

The viral polymerase complex consists of PA, PB1 and PB2, in which PB1 and PB2 interacted with Hsp70 (Fig. 1). Furthermore the binding regions of PB1 and PB2 with Hsp70 (Fig. 2) were pivotal to the RNP functions. We speculated that Hsp70 might affect the integrity of RNP. To test this idea, the MDCK cells were infected with virus and the nuclear fraction was isolated and incubated with His-Hsp70 or BSA as negative control. Then the mixtures were subjected to glycerol gradient centrifugation. The fractions were collected and subjected to immunoblotting with anti-NP, anti-PA, anti-PB2 and anti-Hsp70 antibodies (Fig. 9A) as well as semiquantitative RT-PCR for vRNA and cRNA of NP segment (Fig. 9B). As shown in Fig. 9A, in BSA-treated RNPs PA sedimented predominantly in fractions 1 to 7, PB2 in fractions 1 to 9, NP in almost all fractions except fraction 12, then in Fig. 9B vRNA and cRNA sedimented in fractions 1 to 8, therefore, it was shown that RNP complex sedimented to fractions 1 to 7, because there existed vRNA (cRNA), NP, PA and PB2. In contrast, in Hsp70-treated RNPs vRNA and cRNA sedimented mainly in fractions 6 to 9, NP in fractions 6 to 10, but PA and PB2 in fractions 1 to 4 where Hsp70 sedimented. We concluded that the addition of Hsp70 disrupted the
integrity of RNP, with NP and vRNA (cRNA) binding together, but PA and PB2 were not in the same fractions.

Hsp70 inhibited influenza A virus replication in vivo

In order to investigate whether Hsp70 protein inhibits influenza virus replication in vivo, we prepared the TAT-Hsp70 protein for virus infection assay. It had been reported that TAT-Hsp70 was able to be delivered into cells and mice efficiently [46,47]. We examined the effect of TAT-Hsp70 on viral infection in BALB/c mice. Preliminary experiments with mice infection showed that TAT-Hsp70 protein had not exerted any effect on the virus when they were mixed before intranasal infection (data not shown). On day 3 post-infection the viral lung titers of the TAT-Hsp70-treated mice were much lower than those of control mice treated with PBS or TAT-GFP, 7.21 × 10^4, 4.12 × 10^4 and 33 PFU/0.2 g lung in PBS, TAT-GFP and TAT-Hsp70-treated mice respectively. As shown in Fig. 10C, the body weights of control groups and TAT-Hsp70-treated group have diverged significantly on day 3 post-infection. The survival and body weight were examined daily post-infection. All of TAT-Hsp70-treated mice survived while all of PBS or TAT-GFP-treated mice died on the ninth or tenth day respectively (Fig. 10B). The body weight of TAT-Hsp70-treated group increased but those of control groups declined greatly (Fig. 10C). These results showed that Hsp70 protein could effectively inhibit virus propagation in mice and protect the mice from influenza virus infection.

Discussion

In this study, we revealed a distinct mechanism of Hsp70-mediated regulation of influenza virus polymerase activity.
Co-immunoprecipitation assays showed that Hsp70 could interact with PA subunit of influenza virus polymerase in cells transfected with Hsp70 and PA (Fig. 1A) but the interaction between Hsp70 and PA was undetectable in infected 293T and MDCK cells. The reason may be that the interaction between PA and Hsp70 was relatively weak and the amount of PA protein was much lower in infected cells than that in transfected cells so it was hard to detect the interaction between them. Therefore further experiments such as GST pull-down assay were required to confirm their interaction.

The endogenous Hsp70 was located in cytoplasm [48]. In infected cells Hsp70 was translocated into nucleus where the viral transcription and replication occurred (Fig. 3). Therefore there was spatial possibility for Hsp70 to regulate the viral transcription and replication. But the exact mechanism of how Hsp70 was translocated into nucleus needs further elucidation.

Our results confirmed that Hsp70 interacted with PB1 and PB2 subunits both in vitro and in vivo (Fig. 1 and Fig. 2). We wondered how Hsp70 inhibited the function of RNP complex. Therefore we examined whether Hsp70 affected the integrity of RNP. The data in Fig. 9A, B showed that Hsp70 interfered with the binding of NP and vRNA (cRNA) with viral polymerase complex. In vitro GST pull-down assays affirmed that Hsp70 did not affect the binding of NP with PB1 and PB2 (data not shown). Furthermore, it was reported that PB1 bound to the vRNA and cRNA promoter [4,5]. GST pull-down data (Fig. 2A) indicated that Hsp70 bound to vRNA and cRNA promoter binding domains of PB1. Therefore we speculated that Hsp70 disrupted the integrity of RNP through interfering the binding of PB1 with viral RNA promoter so that viral RNA and RNA-bound NP fell off from the polymerase complex as shown in Fig. 9. Taken together, the results indicated that Hsp70 interfered with the integrity of RNP most likely by blocking the interaction of PB1 with vRNA (cRNA) rather than the association of NP with PB1 and PB2.

Inconsistently with our findings, Dalton RM reported that Hsp70 was not responsible for down-regulation of viral RNAs synthesis by using quercetin to inhibit Hsp70 synthesis [49]. Quercetin has been proved to be involved in many cellular pathways in addition to the inhibition of Hsp70 synthesis. For example, quercetin inhibited NF-kB pathway [50]. It has been reported that NF-kB signaling regulated influenza virus RNA synthesis [51], so quercetin may inhibit viral RNAs synthesis by the inhibition of NF-kB pathway. Therefore, quercetin treatment in influenza virus infected cells may produce the counteractive effect on viral RNAs synthesis through Hsp70 and NF-kB pathway, or other unknown pathways, that may be the reason why Dalton, R. M. did not observe the effect of quercetin treatment on viral RNAs level.

Nowadays although there are some anti-influenza drugs available, but drug resists emerged rapidly after therapeutic use in influenza virus infection [52]. It is necessary to develop new drugs against influenza virus. The peptide originated from viral protein as antiviral agent has been studied recently. It was reported that peptide originated from influenza virus polymerase activity by interfering with the integrity of RNP.

Figure 7. Hsp70 inhibits both transcription and replication of RNPs. HeLa cells were transfected with Hsp70 siRNA and control siRNA for 60 h and infected with rWSN in the presence of 100 µg/ml of CHX for 1 h then cultured with DMEM containing CHX for 7 h, or in the absence of CHX as control. Total cell lysates were prepared for immunoblotting with anti-Hsp70 and anti-β-actin antibodies (A). Total RNA was isolated and subjected to real-time RT-PCR to measure the amounts of mRNA of NP and NS segments. The white bars of control siRNA-transfected cells are set to a relative value of 1, and the black bars represent the relative value compared with control (B). The data represent the means of three independent experiments, each performed in triplicate. Error bars represent standard deviation (n = 3). doi:10.1371/journal.pone.0016546.g007

Previous reports had suggested that Hsp70 could inhibit the viral propagation through blocking the nuclear export of ribonucleoprotein complex [39]. In light of these and our current findings, Hsp70 may have multiple mechanisms of controlling the viral replication during virus infection. Although more studies are needed to understand the detailed regulatory mechanisms of Hsp70 in viral replication, our findings revealed the novel role of Hsp70 in regulating viral polymerase activity by interfering with the integrity of RNP.
proved to facilitate influenza virus propagation [18,19]. Therefore, prostaglandins were not ideal for anti-influenza drug. Recently, TAT peptide was used to deliver exogenous protein into cultured cells and mice [58,59], and it had no effect on influenza virus replication [60]. So we took the approach of TAT peptide mediated transduction method to deliver Hsp70 into mice and found that Hsp70 could inhibit the propagation of influenza virus in vivo. It was the first report that host protein was utilized as influenza virus inhibitor in vivo.

In conclusion, we demonstrate that Hsp70 is the inhibitory host factor for influenza virus by interfering with the viral polymerase activity. Our further research will be focused on the development of inhibitory peptide based on Hsp70 protein and providing the candidates for new anti-influenza drugs.

**Materials and Methods**

**Plasmid construction**

Hsp70 gene was amplified from human cDNA library by PCR and cloned into pCMV-Myc (Clonetech) and pET28c (Novagen). The truncated mutants of Hsp70 (ΔEEVD, aa1-611; ATPase domain, aa1-385; PBD, aa386-641) were inserted into pCMV-Myc and pET28c vectors. NP, PA, PB1, PB2 were cloned into pcDNA3-FLAG, and PB1cFLAG was inserted into pcDNA3.1 (Invitrogen) to generate expression vector for C-terminal FLAG-tagged PB1. The truncated mutants of PB1 and PB2 were cloned into pGEX-4T-2 (Amersham Pharmacia Biotech). pH21-vNS-Luc was polymerase I expressing plasmid carrying an influenza virus-like RNA coding for the luciferase reporter protein (kindly provided by Martin Schwemmle, University of Cologne).
of Freiburg) [53]. pH21-cNS-Luc was generated by cloning cRNA promoter of NS with luciferase into pH21.

Cell lines, virus and antibodies

Madin-Darby Canine Kidney (MDCK) cells, human embryo kidney 293T cells, human lung adenocarcinoma epithelial cell line (A549) and HeLa cells were maintained at 37°C in Dulbecco’s Modified Eagle’s medium (DMEM, Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS, PAA). The recombinant influenza virus A/WSN/33 (rWSN) was generated by 12 plasmids system as described previously [61]. Rabbit anti-Hsp70 and anti-PA antibodies were generated by immunizing the rabbits with GST-Hsp70 (aa618-633) and GST-PA (aa1-256), respectively, then affinity purified. Monoclonal anti-Myc (9E10) and anti-His antibodies, goat anti-PB1 (sc-17602), goat anti-PB2 (sc-17603) and rabbit anti-β-actin (sc-1616) antibodies were purchased from Santa Cruz Biotechnology. Mouse anti-FLAG (M2) antibody was purchased from Sigma. Mouse anti-M1 monoclonal antibody was prepared as described previously [62], Rat anti-NP antibody (generously provided by Wenjun Liu, Institute of Microbiology, Chinese Academy of Sciences) was generated by immunizing the rat with His-NP protein.

Virus infection

Monolayer cultured cells were washed twice with PBS, and then infected with rWSN at an indicated multiplicity of infection (MOI). After virus adsorption for 1 h at 37°C, the cells were washed twice with PBS and incubated at 37°C with culture medium. As for PGA1 treatment, the cells were incubated with 20 μg/ml PGA1 (Sigma) in DMEM post-infection and harvested at indicated time.

Plaque assay

MDCK monolayer cells in 35-mm dishes were washed with PBS, and serial dilutions of virus were adsorbed onto cells for 1 h. Unadsorbed virus was removed by washing with PBS, then monolayer cells were overlaid with DMEM supplemented with 3% low-melting-point agarose and 2 μg/ml TPCK-treated trypsin (Sigma). Visible plaques were counted and viral titers were
Figure 10. Hsp70 inhibits influenza virus replication in vivo. Four-week-old female BALB/c mice were infected rWSN plus PBS, TAT-GFP or TAT-Hsp70 and then injected intraperitoneally with PBS, TAT-GFP or TAT-Hsp70 daily from day 1 to 6 post-infection. Three mice from each group were sacrificed on day 3 post-infection, the viral titers in lungs were analysed by plaque assay (A). The survival (B) and body weight (C) of the remaining mice were monitored daily. Asterisk indicates a P value of <0.01 for viral titer comparing TAT-Hsp70 treated group to PBS and TAT-GFP treated groups. Experiments were performed twice with identical results. Error bars represent standard deviation (n=3).

doi:10.1371/journal.pone.0016546.g010
calculated after 3 days of incubation. All data were expressed as the mean of triplicated samples.

**Transient transfection**

293T cells were grown in 60-mm dishes at 80% confluence and transfected with plasmids using Lipofectamine 2000 transfection reagent (Invitrogen). The medium was replaced with fresh culture medium at 7 h post-transfection.

**Luciferase assay**

293T cells were transiently transfected with plasmids expressing influenza virus NP, PA, PB1, PB2 (100 ng for each) and pHH21-vNS-Luc or pHH21-cNS-Luc (50 ng) with pCMV-β-gal plasmid (50 ng) as control of transfection efficiency. The cell lysates were harvested at 36 h post-transfection and subjected to luciferase assay with Luciferase Assay System (Promega).

**Co-immunoprecipitation assay**

Transfected or infected cells were washed twice with cold PBS and lysed in lysis buffer (1% TritonX-100, 150 mM NaCl, 20 mM HEPES pH 7.5, 10% Glycerol, 1 mM EDTA) with protease inhibitor cocktail (Roche) for 20 min, then centrifuged at 12,000 rpm for 10 min. The supernatants were incubated with indicated antibody at 4°C for 1 h, then the protein-A-Sepharose beads were added and rotated at 4°C for 3 h and washed with lysis buffer. The bound proteins were eluted by boiling with SDS loading buffer for 5 min and subjected to Western blot.

**GST pull-down assay**

GST-fused PB1 or PB2 and the corresponding truncated mutants were bound onto glutathione-Sepharose beads (GE Healthcare), then mixed with His-Hsp70 or its mutants in lysis buffer at 4°C for 60 min, the beads were washed with lysis buffer, and the bound proteins were separated by SDS-PAGE followed by Western blotting with monoclonal anti-His antibody.

**RNA interference**

RNA interference was carried out using siRNA purchased from Invitrogen. The siRNA corresponding to the Hsp70 mRNA sequences 5'-UGC ACC UUG GGC UUG UCU CCG UCG U-3' was used to inhibit endogenous Hsp70 protein expression. Control siRNA sequence was 5'-UGC GUC GUC GAU CGC -3'. Transfection of siRNA into HeLa cells was performed according to the manufacturer’s instructions. In brief, HeLa cells at 50% confluence were transfected with 40 nM siRNA using the Lipofectamine 2000.

**Immunofluorescence**

A549 cells were plated on glass coverslips and infected with virus. At indicated time after infection, the cells were fixed with 4% paraformaldehyde for 10 min and permeabilized with 1% TritonX-100 in PBS for 10 min. Then the cells were incubated with rat anti-NP and rabbit anti-Hsp70 antibodies at 37°C for 1 h, washed with 0.5% NP-40 in PBS and incubated with TRITC-conjugated donkey anti-rabbit antibody and FITC-conjugated goat anti-mouse antibody for 1 h, then stained with 2 μg/ml 4’, 6’-diamidino-2-phenylindole dihydrochloride (DAPI). The cells were mounted and observed under confocal microscope (Leica).

**Glycerol density gradient centrifugation**

MDCK cells were infected with rWSN at MOI of 10 for 1 h and cultured for 6 h, then the cells were harvested and incubated in hypotonic lysis buffer (10 mM Tris, pH 8.0, 10 mM NaCl, 3 mM MgCl2, and 1 mM EGTA with protease inhibitors and RNase Inhibitor) for 10 min, followed by 20 strokes of a Dounce B homogenizer. The lysates were spun down for 5 min at 500 g, and the nuclear pellet was washed three times in wash buffer (hypotonic lysis buffer with 0.1% Nonidet P-40) and then treated with nuclear lysis buffer (20 mM HEPEs, pH 8.0, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, and 0.2 mM EDTA with a mixture of protease and RNase inhibitors) for 30 min. The sample was spun at 14,000 g for 30 min, and the supernatant was designated as the nuclear fraction. The nuclear fraction was incubated with 20 μg of His-Hsp70 at 4°C for 1 h or BSA as negative control, and then loaded onto one step glycerol gradient (1 ml of 70%, 0.75 ml of 50%, 0.375 ml of 40% and 1.3 ml of 33% (wt/vol) glycerol). The gradients were centrifuged at 39,000 rpm for 4 h at 4°C in a SW40Ti rotor (Beckman). Fractions (300 μl) were collected from top to bottom.

**Quantitative real-time RT-PCR**

Total RNA was extracted from cells by TRIZol Reagent (Invitrogen) according to the instruction. The reverse transcription was carried out using sense-specific oligonucleotides for vRNA (5’- AGC GAA AGC AGG 3’ and 5’ AGC AAA AGC AGG 3’), cRNA (5’ AGT AGA AAC AAG G 3’), and mRNA (oligoTdT12). A gylceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific primer (5’ GAT GCA GGG ATG ATG TTC 3’) was also included in the RT reaction mixture for vRNA and cRNA. The quantitative real-time PCR was carried out in 20 μl reaction of a mixture containing primers for each of the eight RNA segments [51] or GAPDH (sense primer 5’ TGC ACC ACC AAC TGC TTA G 3’, antisense primer 5’ GAT GCA GGG ATG ATG TTC 3’) with SYBR green dye (TOYOBO). The amount of viral RNA, expressed as threshold cycle (Ct) values, was normalized by the amount of GAPDH RNA. Primers of semiquantitative RT-PCR for NP gene: sense primer is 5’- CAGATACTGGGCCGCTAAGGAC-3’ and antisense primer is 5’-TTGTCTCCAGAAATAG-3’.

**Mice and virus infection**

TAT was designated as YGRKKRRQRRR, 11-amino-acid peptide of human immunodeficiency virus (HIV) TAT protein. TAT-Hsp70 and TAT-GFP [58,59] were amplified by PCR, inserted into pET28c, expressed in E. coli (DE3) pLyS S and purified. Specific-pathogen-free four-week-old female BALB/c mice were used in the studies. Experiments were performed in accordance with the institutional guidelines. Mice were divided into three groups (15/each group). On day 0, mice were anesthetized with ether and infected intranasally with 108 PFU of rWSN mixed with 200 μl of PBS (group 1), TAT-GFP (group 2) or TAT-Hsp70 (group 3) (1 μg/μl). From day 1 to day 6, mice were injected intraperitoneally once a day with 200 μl of PBS (group 1), TAT-GFP (group 2) or TAT-Hsp70 (group 3) (1 μg/μl). Three mice from each group were sacrificed on day 3 post-infection, and viral titers in lung were determined by plaque assay. The remaining 12 mice in each group were examined daily for their body weight and survival.

**Acknowledgments**

We thank Martin Schwemmle for providing us the influenza A virus mini-replicon plasmids.

**Author Contributions**

Conceived and designed the experiments: XY GL WL. Performed the experiments: GL. Analyzed the data: GL JZ. Contributed reagents/materials/analysis tools: GL XT. Wrote the manuscript: XY GL.
References

1. Plotz SJ, Bouloy M, Ulmanen I, Krug RM (1981) A unique cap(m7GpppNm)-
dependent influenza virus endonuclease cleaves capped RNAs to generate the
nascent RNA and cellular 3'-terminal nucleotides. Nucleic Acids Res 9: 2847–2852.
2. Digard P, Blok VC, Ingis SC (1989) Complex formation between influenza virus
polymerase proteins expressed in Xenopus oocytes. Virology 171: 162–169.
3. Pooh O, Ouwagiet D, Delarue M, Teodoro N (1989) Identification of four conserved
motifs among the RNA-dependent polymerase encoding elements. Emb J 37:
3867–3874.
4. Gonzalez S, Ortin J (1999) Characterization of influenza virus PB1 polymerase
binding to viral RNA: two separate regions of the protein contribute to the
interaction domain. Virology 260: 375–387.
5. Gonzalez S, Ortin J (1999) Distinct regions of influenza virus PB1 polymerase
subunit recognize vRNA and cRNA templates. Emb J 38: 3767–3775.
6. Guillou F, Tarelleau F, Resa-Inflante P, Coloma R, Crepin T, et al. (2008)
The structural basis for cap binding by influenza virus polymerase subunit PB1.
Nat Struct Mol Biol 15: 500–506.
7. Fechter P, Mingay L, Sharps J, Chambers A, Fodor E, et al. (2003) Two
aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial
for cap binding. J Biol Chem 278: 20381–20388.
8. Sanz-Ezquerro JJ, de la Luna S, Ortin J, Nieto A (1995) Individual expression of
influenza virus PA protein induces degradation of cap-dependent proteins. J Virol
69: 2420–2426.
9. Yuan P, Barlam M, Lou Z, Chen S, Zhou J, et al. (2009) Crystal structure of an
avian influenza polymerase PA/N1 reveals an endonuclease active site. Nature
458: 909–913.
10. Dias A, Bovier D, Crepin T, McCarthy AA, Hari DJ, et al. (2009) The
conformational change of influenza virus polymerase resides in the PA subunit.
Nature 458: 914–918.
11. Maier HJ, Kashwagi T, Hara K, Brownlee GG (2008) Differential role of the
host factor Ebp1: selective inhibitor for influenza A virus. J Virol 82: 1263–1270.
12. Deng T, Engelhardt OG, Thomas B, Akoulitchev AV, Brownlee GG, et al.
(2008) Interaction domain. J Virol 73: 631–637.
13. Honda A, Okamoto T, Ishihama A (2007) Host factor Ebp1: selective inhibitor
of the Hsp90 cochaperone cyclophilin 40 with Hsc70. Cell Stress Chaperones 9:
196–204.
14. Lee MT, Bishop K, Medcalf L, Elton D, Digard P, et al. (2002) Definition of the
minimal viral components required for the initiation of unprimed RNA synthesis by
influenza virus polymerase. Nucleic Acids Res 30: 429–438.
15. Kawaguchi A, Nakamura N, Nagata K (2005) Involvement of influenza virus PA
subunit in assembly of functional RNA polymerase complexes. J Virol 79:
732–744.
16. Harai K, Schmidt FI, Crow M, Brownlee GG (2006) Amino acid residues in the
N-terminus of the PA subunit of influenza A virus RNA polymerase play a critical
correlation in protein stability, endonuclease activity, cap binding, and viral
RNA promoter binding. J Virol 80: 7789–7798.
17. Nagata K, Kawaguchi A, Naito T (2008) Host factors for replication and transcription
of the influenza virus genome. Rev Med Virol 18: 247–260.
18. Naito T, Momose F, Kawaguchi A, Nagata K (2007) Involvement of Hsp90 in
viral protein synthesis. FEBS Lett 580: 5755–5760.
19. Hirayama F, Atagi H, Hiraki A, Kim J (2004) Heat shock protein 70 is related to
thermal inhibition of nuclear export of the influenza virus ribonucleoprotein complex.
J Virol 78: 1263–1270.
20. Mayer D, Molokov K, Martinez-Sebrido L, Ghanem A, Thomas S, et al. (2007)
Identification of cellular interaction partners of the influenza virus ribonucleo-
protein complex and polymerase complex using proteomic-based approaches. J
Proteome Res 6: 672–683.
21. Chau W, Zhou H, Kenble G, Jin H (2008) The cold adapted and temperature sensitive
influenza A/Amur/6/60 virus, the master donor virus for live attenuated influenza
vaccines, has multiple defects in replication at the restrictive temperature. Virology
380: 304–311.
22. Li ML, Rao P, Krug RM (1986) RNA polymerase as the active sites of the influenza
virus cap-dependent endonuclease are on different polymerase subunits. Emb J 20:
2078–2086.
23. Poole E, Elton D, Medcalf L, Digard P (2004) Functional domains of the
influenza A virus PB2 protein: identification of NP- and PB1-binding sites.
Virology 321: 120–131.
24. Amici C, Santoro MG (1991) Suppression of virus replication by prostaglandin
A is associated with heat shock protein synthesis. J Gen Virol 72(Pt B): 1877–1883.
25. Mark GE, Taylor JM, Broni B, Krug RM (1979) Nuclear accumulation of
influenza viral RNA transcripts and the effects of cycloheximide, actinomycin D,
and alpha-amanitin. J Virol 29: 744–752.
26. Doepner TR, Nagel F, Dietz GP, Weise J, Tonges L, et al. (2009) Tat-Hsp70-
mediated neuroprotection and increased survival of neuronal precursor cells
intracerebral ischemic rat model. J Neurosci Res 87: 1533–1542.
27. Nagel F, Doham CP, Bahr M, Wosters FN, Dietz GP (2008) Quantitative
evaluation of chaperone activity and neuroprotection by different preparations of
a cell-penetrating Hsp70. J Neurosci Methods 171: 236–252.
28. Mikulska KI, Morimoto RI (1996) Expression of human HSP70 during the
synthetic phase of the cell cycle. Proc Natl Acad Sci U S A 93: 9517–9521.
29. Dalton RM, Mullin AE, Amorijn MJ, Medcalf E, Teale LS, et al. (2006)
Temperature sensitive influenza A virus genome replication results from low
thermal stability of polymerase-kRNA complexes. Virol J 3: 38.
30. Vidiya Priyadarshini R, Senthil Muragan R, Maitreyi S, Ramalingam K,
Karanagaran D, et al. (2010) The flavionoid quercetin induces cell cycle arrest
and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells
through p53 induction and NF-kappaB inhibition. Eur J Pharmacol 649: 84–91.
31. Kumar N, Xia ZT, Liang Y, Ly H, Liang Y (2008) NF-kappaB signal
regulator differentially regulates influenza virus RNA synthesis. J Virol 82:
9800–9809.
32. Nicholson KG, Askh F, Osterman AD, Trottier S, Carewicz O, et al. (2000)
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised
controlled trial. Neuroinflammation Inhibitor Flu Treatment Investigator Group.
Lancet 355: 1845–1850.
33. Ghanem A, Mayer D, Chase G, Tegge W, Frank R, et al. (2007) Peptide-
mediated interference with influenza A virus polymerase. J Virol 81: 7801–7804.
34. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K, et al. (1997) In vivo
antiviral activity of a zinc finger peptide. Antimicrob Agents Chemother 41:
687–692.
35. Pica F, Palamara AT, Rossi A, De Marco A, Amici C, et al. (2000) Delta(12)-
Palm Peptide Inhibits Influenza Virus Polymerase Activity
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e16546
55. Pica F, Palamara AT, Rossi A, De Marco A, Amici C, et al. (2000) Delta(12)-
Palmitoylated Antiviral Peptide Inhibits Influenza Virus Polymerase Activity.
PLoS Pathog 6: e1001142.
56. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K, et al. (1997) In vivo
antiviral activity of a zinc finger peptide. Antimicrob Agents Chemother 41:
687–692.
57. Pica F, Palamara AT, Rossi A, De Marco A, Amici C, et al. (2000) Delta(12)-
Palm Peptide Inhibits Influenza Virus Polymerase Activity.
57. Amici C, Sistonen L, Santoro MG, Morimoto RI (1992) Antiproliferative prostaglandins activate heat shock transcription factor. Proc Natl Acad Sci U S A 89: 6227–6231.
58. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569–1572.
59. Fawell S, Seery J, Duikh Y, Moore C, Chen LL, et al. (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 91: 664–668.
60. Jones JC, Turpin EA, Bulmann H, Brandt CR, Schultz-Cherry S (2006) Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J Virol 80: 11960–11967.
61. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 96: 9345–9350.
62. Koestler TP, Rieman D, Muirhead K, Greig RG, Poste G (1984) Identification and characterization of a monoclonal antibody to an antigen expressed on activated macrophages. Proc Natl Acad Sci U S A 81: 4505–4509.